688177.SS Stock Analysis
68
Uncovered
Bio-Thera Solutions Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Bio-Thera Solutions Ltd. engages in the research, development, and production of innovative drugs and biosimilar drugs for the treatment of tumours, autoimmune diseases, cardiovascular diseases, other threats to human life, and major health diseases. The company is headquartered in Guangzhou, Guangdong and currently employs 936 full-time employees. The company went IPO on 2020-02-21. The firm is committed to the development of a new generation of antibody drugs to treat cancer, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life and health. The firm's main products include adalimumab BAT1406, bevacizumab BAT1706, BAT8001, tocilizumab BAT1806, batifaban BAT2094, BAT8003 and so on.